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rapid diagnostic test, Paracheck PfW, in antenatal
health care in Bangui, Central African Republic
Alexandre Manirakiza1,2*, Eugène Serdouma3,4, Luc Salva Heredeïbona5, Djibrine Djalle1, Nestor Madji6,
Methode Moyen6, Georges Soula2, Alain Le Faou7 and Jean Delmont2Abstract
Background: Both treatment and prevention strategies are recommended by the World Health Organization for
the control of malaria during pregnancy in tropical areas. The aim of this study was to assess use of a rapid
diagnostic test for prompt management of malaria in pregnancy in Bangui, Central African Republic.
Methods: A cohort of 76 pregnant women was screened systematically for malaria with ParacheckPf
W at each
antenatal visit. The usefulness of the method was analysed by comparing the number of malaria episodes requiring
treatment in the cohort with the number of prescriptions received by another group of pregnant women followed-
up in routine antenatal care.
Results: In the cohort group, the proportion of positive ParacheckPf
W episodes during antenatal clinics visits was
13.8%, while episodes of antimalarial prescriptions in the group which was followed-up routinely by antenatal
personnel was estimated at 26.3%. Hence, the relative risk of the cohort for being prescribed an antimalarial drug
was 0.53. Therefore, the attributable fraction of presumptive treatment avoided by systematic screening with
ParacheckPf
W was 47%.
Conclusions: Use of a rapid diagnostic test is useful, affordable and easy for adequate treatment of malaria in
pregnant women. More powerful studies of the usefulness of introducing the test into antenatal care are needed in
all heath centres in the country and in other tropical areas.
Keywords: Rapid diagnostic test, Malaria, PregnancyBackground
Malaria is a major public health problem, especially during
pregnancy. In 2008, malaria affected more than 2 billion
people, nearly 40% of the world population. More than 50
million women live in malaria-endemic areas, of whom
20% become pregnant each year, and half of whom develop
complications of pregnancy due to malaria [1,2]. Placental
inter-villous sequestration of malaria parasites during preg-
nancy can cause growth retardation by reducing nutrient
intake and causing hypoxia [3,4] and thus low birth weight
[3-5]. Placental infection with Plasmodium is associated* Correspondence: amanirak@yahoo.fr
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medium, provided the original work is properwith a 50% risk for low birth weight in areas where malaria
is endemic [6]. Clinical malaria increases the risks for abor-
tion, premature delivery and maternal death [7-9].
Sulfadoxine-pyrimethamine (SP) is a promising means
of preventing the adverse effects of malaria, as first sug-
gested by studies conducted in East Africa [10]. Hence,
the World Health Organization (WHO) has recom-
mended SP as a component of one of three packages to
control malaria in pregnant women in Africa [11]: four
antenatal visits, during which two doses of intermittent
preventive (or presumptive) treatment with SP (IPTsp)
spaced by at least 4 weeks are given by directly observed
treatment; use of insecticide-treated nets (ITNs) to re-
duce the number of infective bites; and immediate, ad-
equate treatment of clinical malaria. IPTsp involves
administration of curative doses to asymptomatic womenss article distributed under the terms of the Creative Commons Attribution
by/2.0), which permits unrestricted use, distribution, and reproduction in any
ly cited.
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doses for those infected with HIV). Because SP can be
embryotoxic, it should be administered only after the
16th week (second trimester) of pregnancy [12,13]. The
efficacy of IPTsp plus ITNs in reducing the burden of
malaria during pregnancy is well proven [14-16] and
cost-effective [17-20].
Lack of compliance of health care personnel with the
new strategies could hamper implementation of IPTsp in
particular [11,21]. Certain aspects of health care strat-
egies determine their acceptability in the field [22]. Thus,
the long-standing practice of prescribing antimalarial
drugs only on the basis of a clinical presumption of mal-
aria could result in under-administration of IPTsp in
antenatal health care services.
Bardaji et al. in Mozambique [23] found that 77.4% of
women attending antenatal clinics had clinical signs or
symptoms suggesting malaria, and 92.9% of these were
prescribed antimalarial drugs without laboratory confirm-
ation of Plasmodium infection. [24]. This practice is likely
to be common in tropical areas of Africa. Our recent
study in the Central African Republic showed that labora-
tory analysis is rare before antimalarial drugs are pre-
scribed for pregnant women [25]. Although widespread
presumptive prescription and use of antimalarial agents
could indisputably lead to prompt clearance of existing
peripheral and placental Plasmodium infection and de-
crease the risk for low birth weight [26], unnecessarily
wide use of antimalarial drugs is avoidable if preventive
methods (IPTsp and LLINs) are used. The increasing re-
sistance of P. falciparum to SP [27,28] jeopardizes the
ability of this drug combination to eliminate the parasite
completely, especially when it is sequestered in the pla-
centa, hence, the importance of systematic screening for
malaria during pregnancy [29], and use of rapid diagnostic
tests (RDTs) is a possible strategy [30,31].
In public health care practice in the Central African Re-
public, malaria is diagnosed by analysing thick and thin
blood smears; RDTs have not yet been introduced. The
aim of this study was to assess the efficacy of systematic
screening for malaria with RDTs during antenatal health
care in reducing over-prescription of antimalarial drugs to
pregnant women. The number of episodes of malaria con-
firmed by a RDT in a prospective cohort of pregnant
women receiving routine antenatal care was compared
with the number of antimalarial prescriptions in a control
group of pregnant women at the same clinics.
Method
Study setting and design
This study was conducted in the two main public mater-
nity clinics of Bangui, Central African Republic, the Cas-
tors Health Centre and the Amitié Hospital, between
October 2009 and October 2011. In Bangui, the climate istropical, with rainfall peaks from April to November and
temperatures ranging from 19 °C to 33 °C. The main mal-
aria parasite is Plasmodium falciparum, and malaria trans-
mission is endemic, with peaks during the rainy season,
although no data are available on the intensity of malaria
transmission. Malaria accounts for more than 40% of mor-
bidity in the country (CAR Ministry of Health, unpub-
lished data).
The objective of the National Malaria Programme is to
reduce morbidity and mortality related to malaria in the
general population, especially among children under
5 years and pregnant women, to reach a coverage rate of
at least 80% with each WHO package [11]. This study
consisted of strict application of the three components of
the WHO package to a cohort of women during their
pregnancy. Longitudinal data on Plasmodium infection
were compared with data collected from a matched con-
trol group followed-up routinely by the antenatal services
staff.
Ethical approval
Because there is no ethical committee in the country, this
project was reviewed and approved by an ad hoc scientific
committee of the University of Bangui in charge of valid-
ating scientific study protocols. The scientific committee
of the ‘Ecole Doctorale des Sciences de la Vie et de la
Santé de l’Université de la Méditerranée, Aix-Marseille’
also approved the study protocol and its amendments.
Sample size
We used 25% as a proxy for the number of malaria epi-
sodes during pregnancy [29], and 50% as a proxy for the
number of women usually prescribed antimalarial treat-
ment [25]. The estimated sample size with 80% power at
the 5% significance level was therefore 60 in each group.
Procedures
Antenatal services staff were informed about the study,
and we collected data in the context of usual non-malaria
antenatal health care, including enrolment. During each
working day, a maximum of two pregnant women from
among those presenting at the clinics were randomly
included in the cohort. The women were of all parities
with a gestational age less than 28 weeks, from whom
written informed consent was obtained. Women who
were temporary residents of Bangui, had had a prior dose
of IPTsp, gave a history of sensitivity to SP, quinine or an
artemisinin derivative, had an illness requiring hospital ad-
mission or declined to join the study were excluded.
At enrolment, all women were given an ITN (supplied
by the National Malaria Control Programme), and a
finger-prick blood sample was obtained for preparation of
slides and for diagnosis of Plasmodium infection with the
ParacheckPf
W RDT (Orchid Biomedical Systems, India).
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pational status and educational level) and also gestational
age, gravidity, parity and HIV serological status.
During follow-up, an IPTsp dose (1500 mg sulfadoxine
and 75 mg pyrimethamine) was administered after 16 weeks
of gestation and a second dose at least 1 month later. Smear
slide analysis and the RDT were performed systematically
during each scheduled antenatal visit or at any unscheduled
visit for women who reported malaria-like symptoms.
Women with any symptom or clinical sign suggesting mal-
aria [23] and with a positive result in the RDT and/or on a
blood smear were given quinine (24 mg/kg of body mass)
for 7 days. Women who reported sensitivity to quinine were
given artemether 300 mg (20 mg) and lumefantrine
(120 mg) if the gestational age exceeded 16 weeks. Women
with a positive result in the RDT or on a thick smear but
with no malaria symptoms were given one IPTsp dose; a
smear was made 8 days later to verify any persistent parasit-
aemia or at any time earlier if a woman presented with
symptomatic malaria, when quinine or artemether-
lumefantrine was administered. All women were prescribed
daily ferrous (400 mg) and folic (5 mg) supplements. All the
antimalarial drugs were supplied by the ‘Unité de Cession
du Médicament’, a public wholesaler that imports generic
drugs.
Each woman in our cohort was matched on gravidity (1
or≥ 2) and age (± 5 years) to another women delivering at
the same maternity clinic within 1 week and from whom
written informed consent was also obtained. Other criteria
for enrolment in the control group were: known last date
of menstruation (or gestational age at delivery), at least
one antenatal visit, known HIV serological status and
sleeping under an ITN. The following data were collected:
socio-demographic information (age, address, occupa-
tional status and educational level), gestational age, gravid-
ity, parity, HIV serological status, number of antenatal
visits and number of malaria treatment episodes (with or
without laboratory confirmation) during pregnancy.
At each antenatal visit, the RDT and blood smears were
performed for each woman in the cohort. At delivery, these
tests were performed on both maternal peripheral blood
and placental blood. The placental blood was collected
from the maternal paracentric side of the placenta after in-
cision, and thick blood films were prepared from a droplet
collected by aspiration through a 21-gauge needle attached
to a 5-ml syringe [32,33]. Newborns were weighed on a
mechanical infant body scale.
Laboratory analysis
The maternal and placental thick smears were air-dried,
stained with 4% Giemsa and analysed under a light micro-
scope (× 100 oil immersion) to detect asexual forms of P.
falciparum. The parasite density in maternal peripheral
blood was determined from the number of parasites per200 leukocytes on the assumption of an average leukocyte
count of 8000/μl of blood. For maternal blood films, a re-
sult was considered negative if no parasites were detected
per 200 leukocytes; for placental blood films, a result was
considered negative if no parasites were detected per 100
microscope fields. All the slides were read independently
by two microscopists. In case of a discrepancy, a third
reading was done.
The RDT was performed according to the manufac-
turer’s guidelines and stored at room temperature (26–
32 °C). Briefly, blood samples from the finger-prick and
placenta were blotted into the sample well of the test de-
vice with the loop provided in the kit. Then, six drops
(almost 300 μl) of clearing buffer were dispersed into the
indicated well. The result was read after exactly 15 min.
It was considered negative if a pink band appeared only
in the control window and positive if, in addition to the
control band, a distinct pink band also appeared in the
test window. If no band appeared, the test was consid-
ered invalid and was repeated with a new device.
Data analysis
Data were double-entered into EpiInfo software version
3.5.3, and the database was checked and data entry errors
corrected with the EpiInfo software ‘data compare’ utility
for finding differences between two tables. Statistical ana-
lysis was conducted with Stata 11.2 and MedCalc v11.6.1.
Categorical variables were compared by either the χ2
test or Fisher exact test, and quantitative variables were
compared by the Student t test (Mann–Whitney U test).
The level of significance (P) was fixed at 0.05 for all stat-
istical tests.
We used the attributable fraction calculation procedure
[34] to estimate avoidance of antimalarial drug prescrip-
tion for pregnant women systematically screened for mal-
aria. Thus, the risk for exposure to antimalarial drugs was
calculated for each group, and then we calculated the rela-
tive risk (RR) of the women in the cohort for being treated
in relation to the control group, and used the 1–RR for-
mula to calculate the preventive fraction.
Results
Participant flow
During the study period, 874 pregnant women presented
at their first antenatal visit. At baseline, 412 women ful-
filled the inclusion criteria. A cohort sample of 83 preg-
nant women was randomly recruited from among women
who fulfilled the inclusion criteria. The remaining 329
women were followed-up routinely by the antenatal ser-
vices staff, providing an eligible population from which
the control group was recruited at delivery. In the cohort
group, 76 women (91.6%) were followed-up until delivery.
At this end-point, this cohort group was matched to the
control group (Figure 1). Overall, the total number of
Figure 1 Study participant flow chart.
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the control group.
Characteristics of the study population
The average age of the women was 26 years (SD=5 years),
and the mean gravidity was 2 (range, 1–6), with no statisti-
cally significant differences between the groups. The sero-
logical prevalence of HIV infection was 7.6% (Table 1).
The distribution of visits by length of gestation (in
months) is shown in Figure 2. The IPTsp coverage rate
with at least two doses was 93.4% in the cohort and 65.8%
(50/76) in the control group. A statistically significant dif-
ference in the mean weight of birth of the infant was
found between the two groups (P= 0.007).
Results of diagnostic tests for malaria
In the cohort, 40 pregnant women (52.6%) presented
clinical signs at baseline suggesting malaria. Of these
women, 42.5% (17/40) had a positive RDT for malaria;
none of the asymptomatic pregnant women had a posi-
tive result for malaria. During follow-up, 293 antenatal
visits were made by the cohort group, and symptoms
suggesting malaria were noted in 35.5% (104/293); how-
ever, positive RDT were found for only 29.8% (31/104).
Overall, positive results for P. falciparum infection were
found by the RDT at 13.8% of antenatal visits (51/369)
and by thick blood smear analysis at 11.6% (43/369) of
visits. Concordance was found for positive results in the
RDT and in thick blood smears but not for negative
results, as eight results were negative in the thick blood
smear but positive with the RDT (15.7% discordance).
Figure 1 shows a flow chart of these diagnostic tests.
Women positive results in the RDT were treated with






Mean age (years) (SD) 25.9 (5.4) 26.7 (3.8) NS
Number of pregnancies
0–1 32.4 (23) 29.6 (21) NS
2 25.4 (18) 26.8 (19) NS
≥ 3 49.3 (35) 50.7 (36) NS
Educational level
None 18.3(13) 14.1 (10) NS
Primary school 33.8 (24) 38.0 (27) NS
Secondary school 54.9 (39) 54.9 (39) NS
HIV serological status 7.9 (6) 5.3 (4) NS
Birth weight, mean g (SD) 3161 (351) 3297 (261) 0.007
Proportion of infants weighing
< 2500 g
5.3 0.0 -
SD, standard deviation(54.9%, 28/51). During follow-up, three asymptomatic
malaria episodes were seen, with positive results in both
the RDT and thick blood smear analysis. Each of these
women received one dose of SP, and thick blood smears
analysed 8 days later and at the following scheduled visit
was negative.
In the control group, 75 prescriptions for a possible
malaria episode were delivered by the antenatal services
staff. Positive thick blood smears were documented on
35.0% of antenatal visit cards. These cards showed that
29.3% (22/75) prescriptions of antimalarial drugs were
achieved after a documented positive laboratory result
for malaria before treatment, while 36.0% (27/75) anti-
malarial drugs were achieved without laboratory analysis.
For remaining prescriptions, laboratory analysis was not
recorded in antenatal visit cards. However, interviewed
women were reported that smear analysis were positive.
At delivery, the results of the two tests were concord-
ant for both the maternal peripheral blood smear and
the placental blood samples in the two groups. Four pla-
cental blood samples from the cohort and only two from
the control group were positive in the RDT. In the con-
trol group, five placental blood samples and two blood
slides were positive with the RDT (Figure 3).
During this study, none of the tests was invalid.Effect of RDT results on malaria treatment
Only 13.8% (51/369) of the pregnant women in our cohort
needed antimalarial treatment after a positive RDT, while
26.3% (75/285) of the control group received such prescrip-
tions. Antimalarial treatment was significantly more fre-
quent in the control group than in the cohort (P=0.0001).
The relative risk of the cohort for being prescribed an anti-
malarial drug was 0.53; therefore, 47% of prescriptions wereFigure 2 Numbers of antenatal visits according to gestational
age in the cohort and control groups of pregnant women.
Figure 3 Results of thick blood smear analysis and Paracheck PfW RDTs in the study and control groups of pregnant women at
delivery.
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treatment according to gestational age was, however, similar
in the two groups (U-test P values> 0.05) (Figure 4).
Discussion
Our findings highlight the value of using an RDT in man-
aging malaria during pregnancy. The usefulness of RDTs
in the diagnosis of malaria in patients presenting with
symptoms or clinical signs is well established [35,36], al-
though there has been concern that the number of malariaFigure 4 Distribution of malaria treatment episodes in the study andcases might be overestimated [37,38]. The performance of
the ParacheckPf W RDT in the diagnosis of malaria in
pregnancy was recently appraised [39], and the use of
RDTs in reducing the cost of treatment of malaria as com-
pared with presumptive treatment has been demonstrated
in children in Cameroon [40]. However, heat stability, vital
to maintaining the sensitivity of this test in the field, is a
concern [41,42], although there were no invalid tests.
The ParacheckPf W RDT was more sensitive than micro-
scopic analysis of thick blood smears, as found in othercontrol groups of pregnant women.
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RDT can be positive when microscopy is negative [43].
The location of parasites in the deep blood circulation,
particularly in the placenta, with release of antigens into
the systemic circulation would explain a negative result in
thick blood slides when an RDT is positive.
We observed a significant reduction in the number of
antimalarial drug prescriptions in pregnant women when
the ParacheckPfW RDT was used at each antenatal visit.
This strategy therefore reduces unnecessary expenditure
on drugs and also reduces unwarranted exposure of preg-
nant women to those drugs. Moreover, appropriate early
treatment of malaria during pregnancy helps to eliminate
parasites from both maternal blood and the placenta.
It has been estimated that malaria parasites are present
in the placenta in only 20% of cases [44,45]. In our study,
this proportion was 15.7%. As parasites sequestered in the
placenta release antigens into the peripheral blood, they
can be detected by RDT at any time of pregnancy.
One potential limitation of our study is the small sam-
ple, which precluded further analysis of birth weights;
however, a study of three cohorts of a total of 3333
women conducted in Ghana [29] led to the same conclu-
sion regarding the usefulness of screening with an RDT
and treatment of positive cases. A second potential limita-
tion was possible bias due to the “Hawthorne effect”,
whereby people improve an aspect of their behaviour be-
cause they know they are being observed [46]. As our
study was conducted in the office used by the staff of the
antenatal clinics, they might have changed their attitude
to improve the diagnosis of malaria by increasing their
requests for laboratory analysis of thick blood smears.
Conclusion
This study shows that routine screening of pregnant
women for malaria can avoid unnecessary prescription of
drugs. As any use of medical products during pregnancy
should be avoided, the proportion of avoidable antimalarial
drug exposure that we observed in this study could be im-
portant if it were extrapolated to other primary health care
services.
Ensuring clearance of malaria parasites is essential for
the control of malaria during pregnancy. Thus, the ease of
use and relatively high sensitivity of the ParacheckPfW RDT
in comparison with microscopy could allow prompt, rad-
ical treatment of malaria. Its integration into primary health
care services should, however, be accompanied by regular
supervision of the activities of the personnel involved.
More studies are needed in other areas of the Central Afri-
can Republic and other countries to assess the introduction
of RDTs in malaria control in pregnant women.
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